Dong Y and colleagues provided the first evidence that cucurbitacin E (CuE) inhibited tumor angiogenesis by inhibiting the vascular endothelial growth factor receptor 2 (VEGFR2)-mediated JAK2/STAT3 and mitogen-activated protein kinase (MAPK) signaling pathways, and CuE might be a potential candidate in angiogenesis-related disease therapy [35]. This evidence concerns the gene KDR and neoplasm.